An Endorsement of the ASTRO/ESTRO 2023 Guideline for the Treatment of Patients with Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer

Guideline Objective

The objective of this guideline is to determine the most effective therapies for patients with oligometastatic or oligoprogressive non-small cell lung cancer (NSCLC)

Patient Population

The target population includes adult patients with oligometastatic or oligoprogressive NSCLC.

Intended Guideline Users

The intended users include oncologists and thoracic surgeons involved in the treatment of patients with oligometastatic or oligoprogressive NSCLC.

Research Questions

1. What are the optimal patient/disease characteristics to select patients with oligometastatic NSCLC for definitive treatment combining systemic and local therapies?
2. What are the selection criteria for choice of local treatment modality in the management of patients with oligometastatic NSCLC?
3. What are the appropriate sequencing and timing of systemic therapy and definitive local therapies for patients with oligometastatic NSCLC?
4. What are the optimal dose-fractionation regimens, planning, and delivery technique of RT for patients with oligometastatic NSCLC?
5. After a definitive local therapy approach for oligometastatic NSCLC, what are the indications for additional local therapy upon disease progression?